A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)
British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2828-2833
DOI: 10.1002/bcp.70588 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 24.04.2026. Verfasst von Katherine Z Isoardi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia. Hauptthemen laut MEDLINE: Rivaroxaban, Drug Overdose, Hemorrhage, Factor Xa Inhibitors. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Aim
There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications.
Methods
This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical toxicology units from August 2014 to August 2024. Data collected included demographics, ingestion details, coagulation profile, rivaroxaban concentrations, significant bleeding (with haemoglobin decrement) and outcome.
Results
There were 58 presentations in 52 patients, 29/52 (56%) males, median age of 49 years (range: 18–93 years). The median reported dose ingested was 200 mg (IQR: 92.5–400 mg, range: 45–1120 mg). Co‐ingestants were taken in 49 (84%), most commonly mirtazapine and paracetamol. A raised international normalized ratio (INR) of >1.5 occurred in 46 (79%) with a median peak INR of 2.5 (IQR: 1.7–3.7). The median duration for an elevated INR to return to ≤1.5 was 22 h (IQR: 14–38 h). Significant bleeding occurred in two patients; both were managed conservatively without factor replacement. Rivaroxaban concentrations were available in 11 cases. There was a strong correlation ( R 2 = 0.83, p < .001) between rivaroxaban concentration and INR. An INR of ≤1.5 was associated with therapeutic rivaroxaban concentrations. There was one death attributed to co‐ingested amlodipine.
Conclusion
Bleeding was uncommon following rivaroxaban overdose. The INR appears to be a good indicator of coagulopathy, with an INR of ≤1.5 approximating therapeutic rivaroxaban concentrations. Observation of patients following acute rivaroxaban overdose until the INR ≤ 1.5 seems reasonable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.
- Queensland Poisons Information Centre, Queensland Children's Hospital, Brisbane, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, Australia.
- Clinical Toxicology Unit, Prince of Wales Hospital, Sydney, Australia.
- New South Wales Poisons Information Centre, Children's Hospital at Westmead, Westmead, Australia.
- School of Medicine, University of New South Wales, Sydney, Australia.
ORCID-Profile: Katherine Z Isoardi, Angela L Chiew, Keith Harris, Geoffrey K Isbister
Förderung
- National Health and Medical Research Council
Zitieren
APA
Isoardi, K. Z., Chiew, A. L., Harris, K., & Isbister, G. K. (2026). A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11). British Journal of Clinical Pharmacology, 92(8), 2828-2833. https://doi.org/10.1002/bcp.70588
Vancouver
Isoardi KZ, Chiew AL, Harris K, Isbister GK. A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11). British Journal of Clinical Pharmacology. 2026;92(8):2828-2833. doi:10.1002/bcp.70588
BibTeX
@article{Isoardi2026,
author = {Isoardi, Katherine Z and Chiew, Angela L and Harris, Keith and Isbister, Geoffrey K},
title = {A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {8},
pages = {2828--2833},
doi = {10.1002/bcp.70588}
}
EUVIMED